JP2014502508A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014502508A5 JP2014502508A5 JP2013546763A JP2013546763A JP2014502508A5 JP 2014502508 A5 JP2014502508 A5 JP 2014502508A5 JP 2013546763 A JP2013546763 A JP 2013546763A JP 2013546763 A JP2013546763 A JP 2013546763A JP 2014502508 A5 JP2014502508 A5 JP 2014502508A5
- Authority
- JP
- Japan
- Prior art keywords
- poliovirus
- stem
- base pairs
- positions
- coding region
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000991587 Enterovirus C Species 0.000 claims 19
- 108091092724 Noncoding DNA Proteins 0.000 claims 5
- 230000035772 mutation Effects 0.000 claims 5
- 229940029583 inactivated polio vaccine Drugs 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 229960005486 vaccine Drugs 0.000 claims 3
- 101800001494 Protease 2A Proteins 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 108090000565 Capsid Proteins Proteins 0.000 claims 1
- 241000282693 Cercopithecidae Species 0.000 claims 1
- 102100023321 Ceruloplasmin Human genes 0.000 claims 1
- 102220539707 Chromosome alignment-maintaining phosphoprotein 1_E65V_mutation Human genes 0.000 claims 1
- 108091026890 Coding region Proteins 0.000 claims 1
- 102220642168 Disintegrin and metalloproteinase domain-containing protein 8_W35R_mutation Human genes 0.000 claims 1
- 102220503492 Transmembrane protease serine 12_Y19H_mutation Human genes 0.000 claims 1
- 230000002238 attenuated effect Effects 0.000 claims 1
- 102220359783 c.234_235invCA Human genes 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 210000005260 human cell Anatomy 0.000 claims 1
- 230000002163 immunogen Effects 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 238000012606 in vitro cell culture Methods 0.000 claims 1
- 230000000415 inactivating effect Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000002245 particle Substances 0.000 claims 1
- 230000002062 proliferating effect Effects 0.000 claims 1
- 230000000644 propagated effect Effects 0.000 claims 1
- 241000897111 recombinant polioviruses Species 0.000 claims 1
- 102200036620 rs104893878 Human genes 0.000 claims 1
- 102220227484 rs1064793232 Human genes 0.000 claims 1
- 102220326980 rs1165815510 Human genes 0.000 claims 1
- 102220257391 rs1553393940 Human genes 0.000 claims 1
- 102220011218 rs281865124 Human genes 0.000 claims 1
- 102200068593 rs281865221 Human genes 0.000 claims 1
- 102220119638 rs35689779 Human genes 0.000 claims 1
- 102220041142 rs587778635 Human genes 0.000 claims 1
- 102200161838 rs62638195 Human genes 0.000 claims 1
- 102200028844 rs679620 Human genes 0.000 claims 1
- 102220011099 rs730881019 Human genes 0.000 claims 1
- 102220060423 rs755605816 Human genes 0.000 claims 1
- 102220215671 rs757793193 Human genes 0.000 claims 1
- 102220075281 rs779993809 Human genes 0.000 claims 1
- 102220075247 rs796052425 Human genes 0.000 claims 1
- 102220082228 rs863224038 Human genes 0.000 claims 1
- 102220203481 rs946076987 Human genes 0.000 claims 1
- 241000894007 species Species 0.000 claims 1
- 210000003501 vero cell Anatomy 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1022077.0 | 2010-12-29 | ||
| GBGB1022077.0A GB201022077D0 (en) | 2010-12-29 | 2010-12-29 | Inactivated poliovaccine |
| PCT/GB2011/001779 WO2012090000A1 (en) | 2010-12-29 | 2011-12-29 | Inactivated poliovaccine |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014502508A JP2014502508A (ja) | 2014-02-03 |
| JP2014502508A5 true JP2014502508A5 (enExample) | 2014-12-18 |
| JP5955860B2 JP5955860B2 (ja) | 2016-07-20 |
Family
ID=43599090
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013546763A Active JP5955860B2 (ja) | 2010-12-29 | 2011-12-29 | 不活化ポリオワクチン |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US9402892B2 (enExample) |
| EP (1) | EP2658571B1 (enExample) |
| JP (1) | JP5955860B2 (enExample) |
| CN (1) | CN103391788B (enExample) |
| AU (1) | AU2011350995B2 (enExample) |
| BR (1) | BR112013017014B1 (enExample) |
| CA (1) | CA2821859C (enExample) |
| DK (1) | DK2658571T3 (enExample) |
| ES (1) | ES2574178T3 (enExample) |
| GB (1) | GB201022077D0 (enExample) |
| RU (1) | RU2599453C2 (enExample) |
| WO (1) | WO2012090000A1 (enExample) |
| ZA (1) | ZA201304415B (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0615933D0 (en) | 2006-08-10 | 2006-09-20 | Nat Inst Biological Standards & Control | Attenuated polioviruses |
| US10238730B2 (en) | 2014-06-17 | 2019-03-26 | Janssen Vaccines & Prevention B.V. | Cold-adapted-viral-attenuation (CAVA) and novel attenuated poliovirus strains |
| GB201700825D0 (en) * | 2017-01-17 | 2017-03-01 | Sec Dep For Health | Poliovaccine |
| US12042533B2 (en) * | 2018-03-30 | 2024-07-23 | Biological Mimetics, Inc. | Irradiation-inactivated poliovirus, compositions including the same, and methods of preparation |
| WO2020075197A1 (en) * | 2018-10-10 | 2020-04-16 | Biological E Limited | Inactivated poliomyelitis vaccine composition |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8901094D0 (en) | 1989-01-18 | 1989-03-15 | Almond Jeffrey W | Attenuated viruses |
| ZA929418B (en) * | 1991-12-06 | 1993-06-07 | Whitehead Biomedical Inst | Recombinant vaccines and method of producing same. |
| GB9705669D0 (en) | 1997-03-19 | 1997-05-07 | British Tech Group | Attenuated polioviruses |
| GB9817082D0 (en) * | 1998-08-06 | 1998-10-07 | Btg Int Ltd | Attenuated poliovirus vaccine |
| GB0615933D0 (en) * | 2006-08-10 | 2006-09-20 | Nat Inst Biological Standards & Control | Attenuated polioviruses |
-
2010
- 2010-12-29 GB GBGB1022077.0A patent/GB201022077D0/en not_active Ceased
-
2011
- 2011-12-29 BR BR112013017014-0A patent/BR112013017014B1/pt active IP Right Grant
- 2011-12-29 CA CA2821859A patent/CA2821859C/en active Active
- 2011-12-29 RU RU2013135290/10A patent/RU2599453C2/ru active
- 2011-12-29 ES ES11807966.4T patent/ES2574178T3/es active Active
- 2011-12-29 CN CN201180063532.4A patent/CN103391788B/zh active Active
- 2011-12-29 US US13/977,399 patent/US9402892B2/en active Active
- 2011-12-29 JP JP2013546763A patent/JP5955860B2/ja active Active
- 2011-12-29 EP EP11807966.4A patent/EP2658571B1/en active Active
- 2011-12-29 DK DK11807966.4T patent/DK2658571T3/en active
- 2011-12-29 AU AU2011350995A patent/AU2011350995B2/en active Active
- 2011-12-29 WO PCT/GB2011/001779 patent/WO2012090000A1/en not_active Ceased
-
2013
- 2013-06-14 ZA ZA2013/04415A patent/ZA201304415B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20140597T1 (hr) | Proizvodnja polio virusa u visokim titrima za proizvodnju cjepiva | |
| Sanders et al. | PER. C6® cells as a serum-free suspension cell platform for the production of high titer poliovirus: A potential low cost of goods option for world supply of inactivated poliovirus vaccine | |
| JP2013179943A5 (enExample) | ||
| JP2014502508A5 (enExample) | ||
| Vu et al. | A synthetic porcine reproductive and respiratory syndrome virus strain confers unprecedented levels of heterologous protection | |
| JP2014532691A5 (enExample) | ||
| Caine et al. | A single mutation in the VP1 of enterovirus 71 is responsible for increased virulence and neurotropism in adult interferon-deficient mice | |
| Hankaniemi et al. | Optimized production and purification of Coxsackievirus B1 vaccine and its preclinical evaluation in a mouse model | |
| NZ577405A (en) | Vaccines including antigen from four strains of influenza virus | |
| JP2013520977A5 (enExample) | ||
| CN105517568B (zh) | 防止病毒组分聚集的方法 | |
| JP2015517304A5 (enExample) | ||
| RU2012142309A (ru) | Рекомбинантный аттенуированный парвовирус | |
| RU2013135290A (ru) | Инактивированная полиовакцина | |
| Sun et al. | Development and evaluation of an inactivated coxsackievirus A16 vaccine in gerbils | |
| Sanders et al. | Production of high titer attenuated poliovirus strains on the serum-free PER. C6® cell culture platform for the generation of safe and affordable next generation IPV | |
| EA201692468A1 (ru) | Аттенуация вируса путем холодовой адаптации (cava) и новые аттенуированные штаммы полиовируса | |
| EA200701695A1 (ru) | Рнк вирусы с ослабленной способностью к репликации в качестве вакцин | |
| JP2012125257A5 (enExample) | ||
| CN106636001B (zh) | 一种重组肠道病毒表型混合系统的构建方法和应用 | |
| CN108055827B (zh) | 高成长肠病毒71型病毒株及其疫苗 | |
| Sanders et al. | Brunenders: a partially attenuated historic poliovirus type I vaccine strain | |
| TWI447226B (zh) | 用於增殖病毒之二步驟溫度型態 | |
| CN102657857A (zh) | 一种利用沙鼠肾细胞制备肠道病毒疫苗的方法 | |
| Yuan et al. | Porcine encephalomyocarditis virus strain BD2 isolated from northern China is highly virulent for BALB/c mice |